Teva Pharma (TEVA) Prelim. Q2 Revenue, EPS Outpace Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Teva Reports Preliminary Second Quarter 2015 Results
July 27, 2015 4:47 AM EDT$4.97 Billion in Revenue and $1.43 in Non-GAAP EPS
Raises 2015 EPS Guidance
JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced preliminary financial results for the second quarter of 2015:
Revenues of approximately $4.97 billion, down 2% compared to the second quarter of 2014. Excluding the impact of foreign exchange fluctuations and the sale of U.S. OTC plants in July 2014, revenues increased 6% compared to the second quarter of 2014. Non-GAAP diluted earnings per share (EPS) of $1.43 in the... MoreTeva Withdraws Proposal to Acquire Mylan
July 27, 2015 4:31 AM EDTJERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it has withdrawn its cash and stock proposal to acquire all of the outstanding ordinary shares of Mylan N.V. (NASDAQ: MYL) and Teva does not intend to continue to pursue a transaction with Mylan at this time. Tevas decision to terminate the proposal to acquire Mylan follows todays announcement that Teva has entered into a definitive agreement with Allergan to acquire Allergan Generics.
In light of our strategic acquisition of Allergan... More
Teva to Acquire Allergan Generics for $40.5 Billion Creating a Transformative Generics and Specialty Company Well Positioned to Win in Global Healthcare
July 27, 2015 4:30 AM EDTAcquisition Strongly Reinforces Teva's Strategy, Accelerates the Creation of Its New Business Model and Opens a New Set of Possibilities for the Company In Generics and Specialty
Opportunity to Further Transform the Global Generics Space through Best-In-Class Generics Pipeline, R&D Capabilities, Operational Network, Supply Chain, Global Commercial Deployment and Infrastructure
Robust Generics Platform to Support Future Strategic Investment in Specialty
Teva Will Be a Top 10 Global Pharmaceutical Company
Enhanced Financial Profile with Strong, Diversified Revenues
... More
